Laura E. Niklason - Jun 13, 2024 Form 4 Insider Report for Humacyte, Inc. (HUMA)

Role
President, CEO and Director, Director
Signature
/s/ Laura E. Niklason by Dale A. Sander as Attorney-in-Fact
Stock symbol
HUMA
Transactions as of
Jun 13, 2024
Transactions value $
$0
Form type
4
Date filed
6/17/2024, 04:12 PM
Previous filing
Jun 13, 2024
Next filing
Aug 29, 2024

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction HUMA Stock Options (right to buy) Award $0 +50K $0.00 50K Jun 13, 2024 Common Stock 50K $7.20 By spouse F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The first 25% of the option becomes exercisable on June 13, 2025, after which 1/48 of the option will become exercisable on the 13th of each month through June 13, 2028.